The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of LDE225 in advanced solid tumors: Updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation.
H. A. Tawbi
No relevant relationships to disclose
J. Rodon Ahnert
Expert Testimony - Novartis
R. Dummer
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
A. L. Thomas
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
C. Granvil
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Y. Shou
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. Dey
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
M. M. Mita
No relevant relationships to disclose
D. D. Amakye
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
A. C. Mita
No relevant relationships to disclose